Drugs / SYS6006
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05354063 | Jun → Sep 2022 | COVID-19 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05354089 | Apr → Jul 2022 | Orthocoronavirinae infectious disease | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07622225 | May 2026 → Dec 2028 expected | neoplasm | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05439824 | Jun 2022 → Jan 2023 | COVID-19 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07834073 | May 2023 → Feb 2024 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT05855408 | May 2023 → May 2024 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05492643 | Aug 2022 → Feb 2023 | COVID-19 | Zhongnan Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2023-12-01 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - BIVALENT COVID-19 mRNA VACCINE (SYS6006.32) INCLUDED FOR EMERGENCY USE IN CHINA irasia.com ↗ |
| 2023-10-30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - BIVALENT COVID-19 mRNA VACCINE (SYS6006.32) OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗
The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the bivalent COVID-19 mRNA vaccine (XBB.1.5/BQ.1 variants) (SYS6006.32) (the “Product”) developed by the Group has obtained clinical trial approval granted by the National Medical Products Administration of the People’s Republic of China. |
| 2023-03-22 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - SARS-CoV-2 mRNA VACCINE (SYS6006) INCLUDED FOR EMERGENCY USE IN CHINA irasia.com ↗
SARS-CoV-2 mRNA VACCINE（SYS6006） INCLUDED FOR EMERGENCY USE IN CHINA |
| 2022-08-23 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Results VOLUNTARY ANNOUNCEMENT - UPDATE ON THE CLINICAL STUDY PROGRESS OF SARS-CoV-2 mRNA VACCINE (SYS6006) irasia.com ↗
The study started enrollment on 27 April 2022 at Shulan (Hangzhou) Hospital, Zhejiang Province, and currently the safety observation as well as immunogenicity evaluation have been completed for all subjects 30 days after the second dose of vaccination. |
| 2022-08-23 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Results VOLUNTARY ANNOUNCEMENT - COMPLETION OF A CLINICAL STUDY OF HETEROLOGOUS BOOSTER IMMUNIZATION OF SARS-CoV-2 mRNA VACCINE (SYS6006) irasia.com ↗
The Company is pleased to announce that a clinical study of heterologous booster immunization (the “Study”) of the SARS-CoV-2 mRNA vaccine (SYS6006) (the “ Product”) developed by the Group was completed, with the expectations for safety and immunogenicity met. |
| 2022-04-03 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - COVID-19 mRNA VACCINE "SYS6006" OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗
The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) announces that the COVID-19 mRNA vaccine “SYS6006” (the “Product”) developed by the Group has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China. |
All press releases naming this drug 6 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYS6006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07834073 ↗ |
| Modality | Messenger RNA (mRNA) | “SARS-CoV-2 mRNA Vaccine (SYS6006)” NCT05354063 ↗ |
| Route | Intramuscular | “20 μg dose of SYS6006 vaccine IM on day 0 and day 21.” NCT05354063 ↗ |